Topic Archives: Boehringer Ingelheim

[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. His words and opinions are his own.] In A History of New York, Washington Irving opens chapter VIII thus: ”In which the author and reader…fall into a very grave and instructive discourse.” This may prove to be a more unleavened column than […]

Comments

  • SoGiAm

    $NTRP, $VTVT, #AD... The Neuroscience Innovation Forum ​' http://www.sachsforum.com/nif-about.html Building on th...

  • DrKSSMDPhD

    Not to dabble in the mystical, but it fascinates me again and again how bad karma can be indelible in biotech. Bad karma...

  • Avatar

    #LN $ABBV $AUPH #Boehringer Ingelheim Phase II trial of BI 655064 for the treatment of lupus nephritis NCT02770170...

  • Avatar

    $PTLA is on the move. As you remember Portola's is seeking approval for its Factor Xa Inhibitor reversal agent Andexanet...

  • Avatar

    eyedoc, excuse my ignorance, but how can Boehringer Ingelheim have a prayer of getting Praxbind approved with statisti...

  • Avatar

    Boehringer Ingelheim has a Pradaxa reversal agent, Praxbind that is being pushed for accelerated approval in October 201...

  • Avatar

    $LLY (no position) As reported this morning by Fierce, Eli Lilly & Co. ($LLY) and Boehringer Ingelheim just scored a c...

  • Avatar

    Sogiam -- I did see that the Dr. was concerned about lack of product in test phases. Now, though they have several and ...

  • DrKSSMDPhD

    Vitae Pharmaceuticals came up last night. $VTAE shares have tripled in value since a late September 2014 IPO, and market...

  • Avatar

    Marinol was sold by Roxanne labs, the generic arm of Boehringer Ingelheim. The indication was for appetite stimulation...

  • DrKSSMDPhD

    Press release from Boehringer Ingelheim just now: BI is abandoning HCV therapeutics. It had already canned deleobuvir...

  • Avatar

    A while back I bought OXBT, after Dr. KSS brought it to the group's attention. I am watching its price with the intenti...

  • We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

    More Info